Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Division of Nuclear Medicine, ASST Spedali Civili, Brescia, Italy.
J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):1042-1055. doi: 10.1002/jcsm.12736. Epub 2021 Jun 11.
Elderly classical Hodgkin lymphoma (cHL) (ecHL) is a rare disease with dismal prognosis and no standard treatment. Fitness-based approaches may help design appropriate treatments. Sarcopenia has been associated with an increased risk of treatment-related toxicities and worse survival in various solid tumours, but its impact in ecHL is unknown. The aim of this retrospective multicentre study was to investigate the prognostic role of sarcopenia in ecHL.
We included newly diagnosed >64 years old cHL patients who performed a baseline comprehensive geriatric assessment and high-dose computed tomography (CT) or 18fluorine-fluorodeoxyglucose positron emission tomography/CT before any treatment. Sarcopenia was measured as skeletal muscle index (SMI, cm /m ) by the analysis of high-dose CT or low-dose positron emission tomography/CT images at the L3 level. The specific cut-offs for the SMI were determined by receiver operator curve analysis and compared with those proposed in literature and studied in diffuse large B-cell lymphoma. Survival functions [progression-free survival [PFS] and overall survival (OS)] were calculated for the whole population and for different subgroups defined as per different sarcopenia cut-off levels.
We included 154 patients (median age 71 years old, 76 female). The median L3-SMI was 42 cm /m . The specific cut-off derived in our male population was 45 cm /m ; using this cut-off, 27 male patients (35%) were defined as sarcopenic. After a median follow-up of 5.9 years, the overall 5-year PFS and OS rates were 53% and 65%, respectively, and were significantly shorter in sarcopenic male patients compared with non-sarcopenic (PFS 31% vs. 61%, P = 0.008; OS 51% vs. 74%, P = 0.042). Applying diffuse large B-cell lymphoma-derived sarcopenic thresholds, there were no significant differences between sarcopenic and non-sarcopenic patients for both PFS and OS, with a sole exception of a significant reduced PFS in sarcopenic male patients using Namakura cut-off. The comprehensive geriatric assessment-determined frail functional status was an independent adverse prognostic factor for both female and male patients.
Baseline evaluation of sarcopenia through radiological examinations performed for ecHL staging may help define a proportion of male patients with unfavourable outcome with current treatment strategies. Also the functional status evaluation could allow to identify a frail subgroup of patients with worse outcome.
老年经典霍奇金淋巴瘤(ecHL)是一种罕见疾病,预后不良,目前尚无标准治疗方法。基于体能的治疗方法可能有助于设计合适的治疗方案。在各种实体瘤中,肌肉减少症与治疗相关毒性和生存预后较差的风险增加相关,但在 ecHL 中的影响尚不清楚。本回顾性多中心研究旨在探讨 ecHL 中肌肉减少症的预后作用。
我们纳入了新诊断的 >64 岁 cHL 患者,这些患者在任何治疗前均进行了基线全面老年评估以及高剂量计算机断层扫描(CT)或 18 氟-氟代脱氧葡萄糖正电子发射断层扫描/CT。肌肉减少症通过分析 L3 水平的高剂量 CT 或低剂量正电子发射断层扫描/CT 图像来测量,作为骨骼肌指数(SMI,cm /m )。SMI 的具体截止值通过接收者操作曲线分析确定,并与文献中提出的并在弥漫性大 B 细胞淋巴瘤中研究的截止值进行比较。为整个人群和根据不同的肌肉减少症截止值水平定义的不同亚组计算生存功能[无进展生存期(PFS)和总生存期(OS)]。
我们纳入了 154 名患者(中位年龄 71 岁,76 名女性)。中位 L3-SMI 为 42 cm /m 。在我们的男性人群中得出的具体截止值为 45 cm /m ;使用该截止值,27 名男性患者(35%)被定义为肌肉减少症。中位随访 5.9 年后,总 5 年 PFS 和 OS 率分别为 53%和 65%,与非肌肉减少症男性患者相比,肌肉减少症男性患者的 PFS 和 OS 明显更短(PFS 31%对 61%,P = 0.008;OS 51%对 74%,P = 0.042)。使用弥漫性大 B 细胞淋巴瘤衍生的肌肉减少症截止值,肌肉减少症和非肌肉减少症患者在 PFS 和 OS 方面均无显著差异,仅 Namakura 截止值的肌肉减少症男性患者的 PFS 显著降低。全面老年评估确定的虚弱功能状态是女性和男性患者的独立不良预后因素。
通过 ecHL 分期进行的放射学检查可以评估基线肌肉减少症,可能有助于确定当前治疗策略下预后不良的男性患者比例。此外,功能状态评估可以识别预后更差的虚弱亚组患者。